India’s API Build-Up Plan To Bridle The Dragon
This article was originally published in PharmAsia News
An Indian expert committee has recommended a raft of measures to revive and promote the production of active pharmaceutical ingredients (APIs) in the country, including the "judicious and liberal" use of anti-dumping duties and safeguards, with an eye on the country's huge reliance on Chinese imports.
You may also be interested in...
With several Chinese manufacturing facilities shut at least till 10 February, Indian pharma companies are keeping a close watch on the evolving coronavirus situation. API inventory can last for a while, but if intermediates supplies don’t resume soon the fallout could be grim.
Prices of active pharmaceutical ingredients and intermediates from China have gone up significantly, piling pressure on Indian and Western companies that rely on it for supplies. Some firms are scrambling to draw up a plan B to secure supplies as the Asian giant weeds out polluting units and ups compliance.
India has come up with a draft policy proposal to end the dependence of the country’s generic drug industry on Chinese bulk drug imports but it’s sketchy on measures, at least so far, to promote domestic production and “needs work.”